Statements (18)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:clinicalTrialPhase |
gptkb:Proxalutamide_for_COVID-19
|
| gptkbp:country |
gptkb:China
|
| gptkbp:focusArea |
oncology
androgen receptor-related diseases |
| gptkbp:foundedYear |
2009
|
| gptkbp:founder |
gptkb:Youzhi_Tong
|
| gptkbp:headquartersLocation |
gptkb:Suzhou,_Jiangsu,_China
|
| https://www.w3.org/2000/01/rdf-schema#label |
Kintor Pharmaceuticals
|
| gptkbp:industry |
gptkb:biotechnology
pharmaceuticals |
| gptkbp:notableProduct |
gptkb:Proxalutamide
gptkb:Pyrilutamide |
| gptkbp:stockExchange |
gptkb:Hong_Kong_Stock_Exchange
|
| gptkbp:stockSymbol |
gptkb:9939.HK
|
| gptkbp:website |
https://www.kintor.com.cn/
|
| gptkbp:bfsParent |
gptkb:Zhangjiang
|
| gptkbp:bfsLayer |
6
|